These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

908 related articles for article (PubMed ID: 17181562)

  • 1. The metabolic syndrome: metabolic changes with vascular consequences.
    Wassink AM; Olijhoek JK; Visseren FL
    Eur J Clin Invest; 2007 Jan; 37(1):8-17. PubMed ID: 17181562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in the relationship between obesity, inflammation, and insulin resistance.
    Bastard JP; Maachi M; Lagathu C; Kim MJ; Caron M; Vidal H; Capeau J; Feve B
    Eur Cytokine Netw; 2006 Mar; 17(1):4-12. PubMed ID: 16613757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lifestyle modification and endothelial function in obese subjects.
    Hamdy O
    Expert Rev Cardiovasc Ther; 2005 Mar; 3(2):231-41. PubMed ID: 15853597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The insulin resistance syndrome: mechanisms of clustering of cardiovascular risk.
    Chan JC; Tong PC; Critchley JA
    Semin Vasc Med; 2002 Feb; 2(1):45-57. PubMed ID: 16222595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adiponectin--a key adipokine in the metabolic syndrome.
    Whitehead JP; Richards AA; Hickman IJ; Macdonald GA; Prins JB
    Diabetes Obes Metab; 2006 May; 8(3):264-80. PubMed ID: 16634986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Of the renin-angiotensin system and reactive oxygen species Type 2 diabetes and angiotensin II inhibition.
    Leiter LA; Lewanczuk RZ
    Am J Hypertens; 2005 Jan; 18(1):121-8. PubMed ID: 15691626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanisms of insulin resistance and associated diseases.
    Mlinar B; Marc J; Janez A; Pfeifer M
    Clin Chim Acta; 2007 Jan; 375(1-2):20-35. PubMed ID: 16956601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Markers of pro-inflammatory and pro-thrombotic state in the diagnosis of metabolic syndrome.
    Odrowaz-Sypniewska G
    Adv Med Sci; 2007; 52():246-50. PubMed ID: 18217426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of adipokines as regulators of skeletal muscle fatty acid metabolism and insulin sensitivity.
    Dyck DJ; Heigenhauser GJ; Bruce CR
    Acta Physiol (Oxf); 2006 Jan; 186(1):5-16. PubMed ID: 16497175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin resistance and inflammation in the early phase of type 2 diabetes: potential for therapeutic intervention.
    Schernthaner GH; Schernthaner G
    Scand J Clin Lab Invest Suppl; 2005; 240():30-40. PubMed ID: 16112958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of insulin resistance on endothelial progenitor cells and vascular repair.
    Cubbon RM; Kahn MB; Wheatcroft SB
    Clin Sci (Lond); 2009 Aug; 117(5):173-90. PubMed ID: 19630751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective role of pravastatin in the pathogenesis of the metabolic syndrome.
    Yamagishi S; Matsui T; Sato T; Takeuchi M
    Med Hypotheses; 2006; 66(3):609-11. PubMed ID: 16171951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome.
    Maury E; Brichard SM
    Mol Cell Endocrinol; 2010 Jan; 314(1):1-16. PubMed ID: 19682539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic effects associated with adipose tissue distribution.
    Zahorska-Markiewicz B
    Adv Med Sci; 2006; 51():111-4. PubMed ID: 17357288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adipokines--targeting a root cause of cardiometabolic risk.
    Bakhai A
    QJM; 2008 Oct; 101(10):767-76. PubMed ID: 18550581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unique atheroprotective property of azelnidipine, a dihydropyridine-based calcium antagonist.
    Nakamura K; Yamagishi S; Inoue H
    Med Hypotheses; 2005; 65(1):155-7. PubMed ID: 15893134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel pathway to the manifestations of metabolic syndrome.
    Sonnenberg GE; Krakower GR; Kissebah AH
    Obes Res; 2004 Feb; 12(2):180-6. PubMed ID: 14981209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adipokines: the missing link between insulin resistance and obesity.
    Antuna-Puente B; Feve B; Fellahi S; Bastard JP
    Diabetes Metab; 2008 Feb; 34(1):2-11. PubMed ID: 18093861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy Insight: adipocytokines in metabolic syndrome and related cardiovascular disease.
    Matsuzawa Y
    Nat Clin Pract Cardiovasc Med; 2006 Jan; 3(1):35-42. PubMed ID: 16391616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypertension and dyslipidaemia in obesity and insulin resistance: pathophysiology, impact on atherosclerotic disease and pharmacotherapy.
    Chapman MJ; Sposito AC
    Pharmacol Ther; 2008 Mar; 117(3):354-73. PubMed ID: 18215759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.